Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Women's ovarian hormones and adrenal androgens change throughout life, affecting hair loss and health.

This study found significant hormonal differences, including elevated cortisol and androstenedione levels, in both male and female androgenic hair loss patients compared to controls, suggesting complex hormonal interactions in the condition.

This study reports that oophorectomy significantly reduces serum testosterone levels in postmenopausal women, indicating the postmenopausal ovary's continued production of testosterone.

This meta-analysis confirmed associations between some androgenic and metabolic parameters in women with PCOS, suggesting that these measurements might help predict metabolic risk in this population.

This study found that male pattern hair loss may be associated with differences in serum levels of androstenedione, cortisol, 17 beta-estradiol, and luteinizing hormone, compared to controls.

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.

This study found a high prevalence of hyperandrogenemia in women with PCOS, with distinct biochemical differences according to BMI and presence of hyperandrogenemia.

This study suggests that alterations in copper metabolism may play a key role in the development of androgenetic alopecia in women, presenting potential targets for treatment strategies.

In this study of hirsute women, researchers found that correlations between hirsutism and hyperandrogenism were observed only in patients with a low LH/FSH ratio.

This case study reports that hormonal imbalances in a young boy with precocious pseudopuberty returned to normal after the removal of a testicular interstitial cell tumor, with normal spontaneous puberty following.

This review discusses ovarian hyperthecosis as a rare cause of androgenetic alopecia in postmenopausal women and reports no new results; the authors highlight the need to explore its relationship to alopecia further.

This study found that both cyproterone acetate alone and combined with ethinyl oestradiol reduced androgen levels and slightly increased SHBG binding in women with hirsutism, but showed no difference in hair regrowth rate between the treatments.

In this study, oral cyproterone acetate reduced hair density and diameter in women with idiopathic hirsutism, but the effects were not permanent after stopping treatment, and plasma androgen levels remained unchanged.

This study reported that administering finasteride reduced levels of certain neuroactive androgens in rat brains, suggesting peripheral origin for most 3α,5α-Adiol and brain synthesis for 3α,5α-A.

This study reported that structure-guided engineering of CYP154C2 mutants significantly improved the 2α-hydroxylation of androstenedione and testosterone, with enhanced conversion efficiency and substrate selectivity compared to the wild-type enzyme.

This study found that a self-assessed modified Ferriman-Gallwey score of 10 or higher indicates excess body hair, and suggests androstenedione measurement should accompany testosterone when evaluating hyperandrogenism.

Sex steroids, especially progesterone, can slow down the growth of mouse melanoma cells.

This study found that in female patients with androgenic hair loss and hirsutism, complex hormonal disturbances include elevated cortisol and thyroid hormone imbalances, rather than elevated androgen levels alone.

This study suggests that circulating androgens produced by the testes have limited clinical relevance to major depressive disorder in adult men, but certain androgens may be linked to specific MDD symptoms.

This study shows that measuring 17-hydroxyprogesterone concentrations in scalp hair may be a useful noninvasive tool for monitoring treatment in adults with congenital adrenal hyperplasia.

This review examines the methods and challenges in androgen laboratory diagnostics, discussing their advantages, limitations, and evolution; it presents no new experimental results.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

This study found that LC-MS/MS assays provided more reliable and precise steroid measurements in human serum compared to traditional immunoassays, particularly at lower concentrations.

This study found that PCOS is common among Iranian women, with phenotypes involving hyperandrogenism exhibiting worse lipid profiles and higher rates of metabolic syndrome compared to healthy women.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

Blood AMH levels are higher in women with PCOS than in those with other similar conditions.

In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.

This study assessed various androgens' diagnostic effectiveness for hyperandrogenaemia in PCOS using ROC curve analysis, but it reports no specific new results.

This study observed that adding simvastatin to ongoing metformin treatment reduced certain androgen levels in women with non-classic congenital adrenal hyperplasia and abnormal glucose metabolism, suggesting a potential therapeutic benefit.

This article discusses the mechanisms of hirsutism and acne in women, highlighting cyproterone acetate with ethinyloestradiol as an effective anti-androgen therapy in the UK, but it reports no new clinical findings.